Compare Arko Corp. (ARKO) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Arko Corp. vs IDEXX Laboratories, Inc. — how do they compare? Arko Corp. trades at $4.47 (market cap $493.06M), while IDEXX Laboratories, Inc. trades at $569.65 (market cap $46.22B). The key difference: IDEXX Laboratories, Inc. is far larger — about 93.7× Arko Corp.'s market cap, and Arko Corp. pays a 2.73% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| ARKO | IDXX | |
|---|---|---|
Market Cap | $493.06M | $46.22B |
Sector | Consumer Cyclical | Health |
52-Week High | $8.64 | $766.68 |
52-Week Low | $3.82 | $526.44 |
Enterprise Value | $2.67B | $47.12B |
Dividend Yield | 2.73% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKO trades at $4.46, down 5.11% on the day, reflecting bearish technical signals and recent earnings miss. The company maintains a low P/S ratio of 0.06 and pays consistent dividends, but faces declining revenue and thin net margins. Recent news highlights weak Q2 2026 results and softer retail demand, with analysts holding a neutral stance.
Outlook remains cautious due to earnings volatility and competitive pressures, though the dividend yield and low valuation offer some value. Key risks include consumer spending sensitivity and high debt levels, requiring close monitoring of margin defense strategies and fuel pricing discipline for recovery.
IDEXX Laboratories (IDXX) trades at $570.58, down 4.23% over 24 hours, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $4.27 surpassing the $3.94 expectation. Revenue growth remains robust, supported by a 74.21% ROE and expanding diagnostic offerings. Recent news highlights product expansion, including a dual-species cardiac test, reinforcing its market leadership in veterinary diagnostics.
The outlook is positive, driven by durable competitive advantages and international growth potential. However, elevated valuation multiples and competitive pressures pose risks. Analyst consensus is bullish with a $683.33 price target, suggesting significant upside from current levels, though investors should monitor execution on guidance and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Arko Corp.
ARKO Corp operates as a holding company. The company, through its subsidiaries, owns and operates convenience stores in the United States. Some of its regional store brands include Stop, Admiral, Apple Market, BreadBox, E-Z Mart, fas mart, Li'l Cricket, and Next Door Store. Its retail store offers hot food service, beverages, cigarettes & other tobacco products, candy, salty snacks, grocery, beer, and general merchandise. ARKO operates in three segments: Retail, Wholesale, and GPM Petroleum. The company derives the majority of its revenue from retail and wholesale distribution of fuel.
Read more on ARKO →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
